middle.news
How Patrys’ Reliis Acquisition Could Transform Acute-Care Delirium Treatment
9:46am on Wednesday 28th of January, 2026 AEDT
•
Healthcare
Read Story
How Patrys’ Reliis Acquisition Could Transform Acute-Care Delirium Treatment
9:46am on Wednesday 28th of January, 2026 AEDT
Key Points
Acquisition of Reliis Pty Ltd finalised, making it a wholly owned subsidiary
RLS-2201 injectable quetiapine program added to Patrys’ clinical-stage pipeline
Two new Non-Executive Directors appointed to Patrys’ Board
Focus on advancing RLS-2201 for delirium management in acute-care settings
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PATRYS (ASX:PAB)
OPEN ARTICLE